Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRUS Stock Forecast 2026-2027
$90.00
Current Price
$6.83B
Market Cap
Buy 1
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to MRUS Price Targets
+7.8%
To High Target of $97.00
+7.8%
To Median Target of $97.00
+7.8%
To Low Target of $97.00
MRUS Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+61.8%
1 Year Change
0.0%
Year-to-Date Change
-7.4%
From 52W High of $97.14
+171.2%
From 52W Low of $33.19
📊 TOP ANALYST CALLS
Did MRUS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Merus is one of their latest high-conviction picks.
Latest MRUS Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, MRUS has a neutral consensus with a median price target of $97.00 (ranging from $97.00 to $97.00). The overall analyst rating is Buy (6.4/10). Currently trading at $90.00, the median forecast implies a 7.8% upside. This outlook is supported by 1 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew Berens at Leerink Partners, projecting a 7.8% upside. Conversely, the most conservative target is provided by Andrew Berens at Leerink Partners, suggesting a 7.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRUS Analyst Ratings
1
Buy
9
Hold
0
Sell
MRUS Price Target Range
Low
$97.00
Average
$97.00
High
$97.00
Current: $90.00
Latest MRUS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRUS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 6, 2025 | Leerink Partners | Andrew Berens | Market Perform | Downgrade | $97.00 |
| Sep 30, 2025 | Barclays | Etzer Darout | Equal-Weight | Downgrade | $97.00 |
| Sep 30, 2025 | Wells Fargo | Eva Fortea Verdejo | Equal-Weight | Downgrade | $97.00 |
| Sep 30, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Neutral | Downgrade | $97.00 |
| Sep 30, 2025 | LifeSci Capital | Charles Zhu | Market Perform | Downgrade | $97.00 |
| Sep 30, 2025 | UBS | David Dai | Neutral | Downgrade | $97.00 |
| Sep 30, 2025 | Guggenheim | Michael Schmitz | Neutral | Downgrade | $97.00 |
| Sep 30, 2025 | Canaccord Genuity | John Newman | Hold | Downgrade | $97.00 |
| Sep 29, 2025 | Wells Fargo | Eva Fortea Verdejo | Equal-Weight | Downgrade | $97.00 |
| Sep 29, 2025 | Truist Securities | Asthika Goonewardene | Hold | Downgrade | $97.00 |
| Sep 29, 2025 | Needham | Ami Fadia | Hold | Downgrade | $96.00 |
| Sep 29, 2025 | Citigroup | Yigal Nochomovitz | Neutral | Downgrade | $97.00 |
| Sep 17, 2025 | Barclays | Etzer Darout | Overweight | Initiates | $112.00 |
| Aug 25, 2025 | Alliance Global Partners | Matt Venezia | Buy | Initiates | $90.00 |
| Aug 7, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Aug 6, 2025 | Needham | Ami Fadia | Buy | Maintains | $96.00 |
| May 23, 2025 | BMO Capital | Evan David Seigerman | Outperform | Maintains | $110.00 |
| May 23, 2025 | Needham | Ami Fadia | Buy | Maintains | $88.00 |
| May 19, 2025 | Needham | Ami Fadia | Buy | Reiterates | $75.00 |
| May 8, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $89.00 |
Merus N.V. (MRUS) Competitors
The following stocks are similar to Merus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Merus N.V. (MRUS) Financial Data
Merus N.V. has a market capitalization of $6.83B with a P/E ratio of -26.9x. The company generates $56.61M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +3.2% quarter-over-quarter, while maintaining an operating margin of -794.1% and return on equity of -51.6%.
Valuation Metrics
Market Cap
$6.83B
Enterprise Value
$6.20B
P/E Ratio
-26.9x
PEG Ratio
-0.2x
Price/Sales
120.6x
Growth & Margins
Revenue Growth (YoY)
+3.2%
Gross Margin
N/A
Operating Margin
-794.1%
Net Margin
0.0%
EPS Growth
+20.4%
Financial Health
Cash/Price Ratio
+9.3%
Current Ratio
8.0x
Debt/Equity
1.6x
ROE
-51.6%
ROA
-26.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Merus N.V. (MRUS) Business Model
About Merus N.V.
What They Do
Develops innovative cancer therapies using bispecific antibodies.
Business Model
Merus N.V. operates as a clinical-stage biopharmaceutical company, generating revenue primarily through the development and commercialization of its bispecific antibody therapeutics. The company leverages its proprietary Biclonics® technology platform to create treatments targeting various tumor types, which addresses crucial needs in oncology. Additionally, it engages in strategic collaborations and clinical trials to advance its drug pipeline, potentially leading to partnerships and licensing agreements that can further enhance revenue streams.
Additional Information
Based in the Netherlands, Merus N.V. is dedicated to improving patient outcomes in cancer treatment and is positioned as a significant player in the biopharma industry. Its focus on immuno-oncology aligns with current trends in cancer research, highlighting its potential for future growth and innovation in therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
260
CEO
Dr. Jan G.J. van de Winkel Ph.D.
Country
Netherlands
IPO Year
2016
Website
www.merus.nlMerus N.V. (MRUS) Latest News & Analysis
Latest News
Quick Summary
LeonaBio, Inc. is advancing its Phase 3 trial of Lasofoxifene for treatment-resistant ER-positive breast cancer, expecting enrollment completion by Q4 2026 and data in 2H 2027.
Why It Matters
The advancement of Lasofoxifene in treatment-resistant breast cancer represents a significant market opportunity, potentially impacting LeonaBio's valuation and future revenue.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Merus Power Oyj has secured a €13 million battery energy storage contract with Neve Oy, enhancing its position in the energy storage market.
Why It Matters
Merus Power's €13 million battery storage deal signals growth in clean energy solutions, likely enhancing its market position and attracting investor interest in renewable technologies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Genmab A/S confirmed that conditions for its tender offer to acquire all common shares of Merus N.V. at $97 per share have been met, advancing its strategic focus.
Why It Matters
Genmab's successful tender offer for Merus enhances its strategic position and growth potential, likely influencing stock performance and investor sentiment positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Bicara Therapeutics (BCAX) is rated Buy due to strong Phase 1b results for its HNSCC candidate, Ficera, and has FDA Breakthrough Therapy Designation and solid cash reserves.
Why It Matters
Bicara Therapeutics (BCAX) gains momentum with a Buy rating, strong Phase 1b data for Ficera, FDA designation, and cash reserves, enhancing its attractiveness against competitors.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Merus N.V. has announced developments from its locations in San Diego, Utrecht, and Cambridge, as of November 17, 2025. Further details were not provided in the excerpt.
Why It Matters
The mention of Merus N.V. indicates potential developments or partnerships that could affect its stock performance and market position, influencing investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
3 Investable Laggards In An Overbought Market
8 months ago
Quick Summary
The market is in overbought territory, with recent gains led by tech giants due to the AI Revolution. Equities are at all-time highs despite ongoing government shutdown and U.S.-China trade tensions.
Why It Matters
Overbought conditions signal potential market corrections. Heavy reliance on tech for gains raises risks, especially amid geopolitical tensions and economic uncertainties.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About MRUS Stock
What is Merus N.V.'s (MRUS) stock forecast for 2027?
Based on our analysis of 24 Wall Street analysts, Merus N.V. (MRUS) has a median price target of $97.00. The highest price target is $97.00 and the lowest is $97.00.
Is MRUS stock a good investment in 2027?
According to current analyst ratings, MRUS has 1 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $90.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRUS stock?
Wall Street analysts predict MRUS stock could reach $97.00 in the next 12 months. This represents a 7.8% increase from the current price of $90.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Merus N.V.'s business model?
Merus N.V. operates as a clinical-stage biopharmaceutical company, generating revenue primarily through the development and commercialization of its bispecific antibody therapeutics. The company leverages its proprietary Biclonics® technology platform to create treatments targeting various tumor types, which addresses crucial needs in oncology. Additionally, it engages in strategic collaborations and clinical trials to advance its drug pipeline, potentially leading to partnerships and licensing agreements that can further enhance revenue streams.
What is the highest forecasted price for MRUS Merus N.V.?
The highest price target for MRUS is $97.00 from Andrew Berens at Leerink Partners, which represents a 7.8% increase from the current price of $90.00.
What is the lowest forecasted price for MRUS Merus N.V.?
The lowest price target for MRUS is $97.00 from Andrew Berens at Leerink Partners, which represents a 7.8% increase from the current price of $90.00.
What is the overall MRUS consensus from analysts for Merus N.V.?
The overall analyst consensus for MRUS is neutral. Out of 24 Wall Street analysts, 1 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $97.00.
How accurate are MRUS stock price projections?
Stock price projections, including those for Merus N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2026 10:45 AM UTC